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LETTERS TO THE EDITOR
To the Editor:
I have read with great interest the
article “Prognostic Factors for Survival in
Extensive Stage Small Cell Lung Cancer”
by Ou et al.1 However, I have a few
questions for the authors.
The study covers a 15-year period
(1991–2005) and the authors report a
median follow-up of 12 months for lim-
ited disease stage and of 5 months for
extensive disease (ED) stage. The date
of point should have been provided, but
this duration of follow-up is surprising.
This would mean that if the date of point
was December 31, 2005 half of the pa-
tients with limited disease stage were
diagnosed after December 31, 2004 and
half of the patients with ED after July
2005 . . . which seems quite impossible.
Is not there a mistake regarding the
definition of follow-up?
One may expect that there was a
period effect, for example, for adminis-
tration of chemotherapy and radiother-
apy. The relatively low rate of treatment
with chemotherapy (68.8%) in this highly
chemosensitive tumor is striking especially
regarding the fact that this is a global per-
centage without taking into account that
the percentage was probably even lower
during the first years. As a matter of fact,
in a population-based study performed
in the Bas-Rhin (a North Eastern depart-
ment of France) and covering 16 years,
68.2% of the patients with ED were
treated with chemotherapy during years
1981–1983, but there was a progressive
increase in this percentage with time and
93% received chemotherapy in the ye-
ars 1993–1994.2 In another population-
based study performed in the Nether-
lands from 1975 to 1994, the percentage
of patients with ED receiving chemo-
therapy (with or without radiotherapy)
during the 1990–1994 period was 81%
for the 128 patients aged less than 70
years and 53% for the 68 patients aged
more than 70 years, which represent a
global percentage of 72%.
The period effect should also be
taken into account for survival analysis,
because there is probably an improve-
ment over time of the survival as in the
above cited articles1,2 or in the SEER
database with a 2-month improvement
of median survival time from 1972 to
19943 and also an increase of survival of
the general population, which is better
analyzed using relative survival rather
than crude survival.
Smoking history does not seem as
a prognostic factor in univariate analysis
of survival with a 1-year, 2-year, and me-
dian overall survival time of 20.9%, 5.5%,
and 6 months, respectively, in smokers
and 21.9%, 6.9%, and 6 months, respec-
tively, in neversmokers (p  0.7455).
However, it does seem as a significant
independent prognostic factor in multi-
variate analysis. This is quite inexplica-
ble regarding the very similar rates of
survival in univariate analysis. Usually,
only variables that are significant in uni-
variate analysis of survival or at least
with a p value less than 0.3 are included
in the multivariate analysis. Here, the
p value was 0.7455.
I would be happy to read the an-
swers of the authors to these comments.
Elisabeth Quoix, MD
Service de Pneumologie
University Hospital
Strasbourg Cedex
France
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In Response:
We appreciate Prof. Quoix’s thou-
ghtful comments.
1. Follow-up duration is the length of
time patients were followed up in
the cancer registry: from the date
of diagnosis until date of death or
date of a censoring event (date of
last contact if patients were lost to
follow-up or the end of follow-up
period, December 31, 2006). The
median follow-up duration was cal-
culated across the study period of 15
years and the range provided in the
text. The longer the patient survived
and did not encounter a censoring
event, the longer the follow-up du-
ration and vice versa. Follow-up du-
ration was not related to the propor-
tion of patients diagnosed before
and after a certain date.
2. We did not set out to determine
whether chemotherapy has improved
overall survival (OS) of extensive
stage small cell lung cancer (ED-
SCLC) over time in our article.
We believe that between 1991 and
2005 therapeutic advances in ED-
SCLC has lagged behind advances
in advanced nonsmall cell lung
cancer such as the approval of oral
epidermal growth factor receptor
inhibitor and combination of anti-
angiogenesis agent bevacizumab
with chemotherapy in nonsmall cell
lung cancer. Any improvement in
ED-SCLC survival is likely due to
stage migration, improved sup-
portive care, and (as Dr. Quoix
mentioned) is likely confounded
by improved survival of the gen-
eral population. Dividing 1991-
2005 into three equal periods (1991–
1995, 1996–2000, 2001–2005), the
percentage of ED-SCLC patients
who received chemotherapy de-
creased from 73.0% to 67.6% to
64.2%. However, the median OS of
ED-SCLC patients who received
chemotherapy was exactly 8 months,
whereas those who did not receive
chemotherapy was 1 month re-
gardless of period. There are many
limitations of using cancer registry
data to analyze the potential bene-
fit of chemotherapy. Standardized
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cific chemotherapy agents are un-
known, performance statuses of the
patients are unknown, and (as men-
tioned in the Discussion section of
the article) the use of prophylactic
cranial irradiation is unknown.
3. We agree with Prof. Quoix’s com-
ments regarding smoking history.
Analyzing OS by smoking status
alone is likely confounded by the
other prognostic factors. Moreover,
the absolute number of never smok-
ers with ED-SCLC was small (N 
93) when compared with ever smok-
ers with ED-SCLC, which likely
make the univariate analysis not
significant. However, given that th-
ere was numerical improvement in
1-year and 2-year survival estimates
of never-smokers over ever-smokers
in ED-SCLC, we included smoking
status in the Cox multivariate an-
alysis including patients with un-
known smoking status. Thus, all pa-
tients listed in Table 1 were included
in the Cox analysis and ever-smoker
status was found to be an unfavor-
able prognostic factor for survival.
Sai-Hong Ignatius Ou, MD, PhD
Jason A. Zell, DO, MPH
Chao Family Comprehensive Cancer
Center
University of California Irvine Medical
Center
Orange, CA
ERCC1 and RRM1
Expression in Nonsmall
Cell Lung Cancer—The
Good, the Bad and the
Unknown
To the Editor:
We read with interest the recently
published in-depth analysis and review by
Hirsch et al.,1 on the prognostic and pre-
dictive role of histology in advanced non-
small cell lung cancer (NSCLC). In this
article, it was mentioned that high-exci-
sion repair cross-complementation group
1 (ERCC1) gene expression was associ-
ated with shorter survival in patients with
advanced NSCLC. This was however
based on the findings of a retrospective
study involving 61 patients.2 In contrast,
the International Adjuvant Lung Cancer
Trial Bioinvestigators group had found
that among the 372 patients in the control
group who did not receive adjuvant che-
motherapy after surgery for early stage
NSCLC, the 5-year overall survival (OS)
rate was significantly higher among pa-
tients with ERCC1-positive tumors than
with ERCC1-negative tumors (46% ver-
sus 39%; adjusted hazards ratio  0.66;
95% confidence intervals  0.49–0.90;
p 0.009).3 Moreover, a close correlation
has been identified between levels of
ERCC1 and ribonucleotide reductase sub-
unit M1 (RRM1). It has been demon-
strated that patients with high expressions
of both ERCC1 and RRM1 have signifi-
cantly longer OS and progression-free sur-
vival compared with those with high ex-
pressions of either of these two proteins
alone as well as compared with those with
low expression of both.4
It has been suggested that intact
DNA repair mechanisms as reflected by
high expressions of both RRM1 and
ERCC1 may represent favorable prognos-
tic factors for untreated patients with
NSCLC.5 Moreover, presence of a higher
capacity of these repair mechanisms could
serve to not only retard progression in
established cancers but also prevent can-
cer per se. This hypothesis can be
assessed by prospective studies that
compare the levels of ERCC1 and
RRM1 in patients with normal, smok-
ing-damaged, and preneoplastic bron-
chial epithelia with those patients hav-
ing established NSCLC.5
It is likely that in addition to
ERCC1 and RRM1, there are several
other genetic and molecular determinants
for treatment response and survival in
NSCLC patients, which have not yet been
clearly identified. This could be one of the
reasons why a phase III randomized trial
that assessed outcomes using ERCC1 tai-
lored chemotherapy among patients with
advanced NSCLC could not demonstrate
any difference between the genotypic and
control arms in terms of progression-free
survival and OS despite a higher response
rate in the former.6 Polymorphisms in
ERCC1 gene have been shown to affect
OS and treatment-related toxicity prev-
iously.7,8 It is possible that polymorphisms
of other genes as well could affect out-
comes in patients with NSCLC.
So, although it may be good for
patients receiving platinum compounds
and gemcitabine to have low ERCC1 and
RRM1 levels, respectively, bad for un-
treated patients to have low ERCC1 and
RRM1 levels, it is still unknown whether
the predictive and prognostic value of
ERCC1 and RRM1 expression in early
NSCLC differs compared with that in ad-
vanced disease. It would be helpful if a
gene-expression profile (metagene) model
similar to that identified for early stage
NSCLC could be developed for advanced
disease as well because it could help to
predict the risk of recurrence and survival
in patients with advanced NSCLC.9
Navneet Singh, MD, DM, FCCP
Ashutosh N. Aggarwal, MD, DM
Department of Pulmonary Medicine
Postgraduate Institute of Medical Education
and Research
Chandigarh, India
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